Liraglutide + Placebo

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Gestational Diabetes Mellitus

Conditions

Gestational Diabetes Mellitus

Trial Timeline

Jul 1, 2012 → Sep 1, 2020

NCT ID

NCT01795248

About Liraglutide + Placebo

Liraglutide + Placebo is a approved stage product being developed by Novo Nordisk for Gestational Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT01795248. Target conditions include Gestational Diabetes Mellitus.

What happened to similar drugs?

4 of 9 similar drugs in Gestational Diabetes Mellitus were approved

Approved (4) Terminated (1) Active (4)

✅Insulin LISPRO + Insulin, Long-Acting and InsulinEli LillyApproved

✅Metformin + placeboNovo NordiskApproved

✅Genotropin (somatropin)PfizerApproved

✅OmnitropeSandoz GroupApproved

🔄somatropinEli LillyPhase 3

❌Recombinant human growth hormone (r-hGH)MerckPhase 3

🔄Saizen® + Saizen®MerckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04775082	Phase 3	Active	Mar 4, 2021	Jan 15, 2027	Obesity
NCT03712098	Phase 2	Completed	Nov 29, 2018	May 25, 2022	Smoking Cessation
NCT03523273	Phase 2	Completed	Nov 29, 2017	Aug 31, 2021	Obesity
NCT02953665	Phase 2	Completed	Apr 3, 2017	Aug 3, 2022	Parkinson Disease
NCT02964247	Phase 3	Completed	Mar 3, 2017	May 8, 2018	Diabetes
NCT02963935	Phase 3	Completed	Feb 6, 2017	Jun 19, 2018	Metabolism and Nutrition Disorder
NCT03038620	Approved	Completed	Jan 1, 2017	Oct 13, 2020	Obesity, Visceral
NCT02889510	Phase 3	Completed	Oct 4, 2016	Dec 16, 2019	Type 2 Diabetes
NCT02918279	Phase 3	Completed	Sep 29, 2016	Aug 8, 2019	Metabolism and Nutrition Disorder
NCT02717858	Phase 1	Completed	Mar 16, 2016	Feb 27, 2017	Metabolism and Nutrition Disorder
NCT02696148	Phase 1	Completed	Mar 14, 2016	Apr 13, 2017	Metabolism and Nutrition Disorder
NCT02655770	Approved	Completed	Feb 1, 2016	Dec 1, 2019	Diabetes Mellitus Type 2
NCT02647944	Phase 2	Completed	Dec 18, 2015	Dec 30, 2016	Obesity
NCT02527200	Phase 3	Completed	Nov 9, 2015	Nov 19, 2020	Metabolism and Nutrition Disorder
NCT02473809	Approved	Completed	Aug 1, 2015	Oct 1, 2017	Diabetes Complications
NCT02545738	Approved	Completed	Apr 1, 2015	May 1, 2016	Diabetic Kidney Disease
NCT02284230	Phase 2	Withdrawn	Dec 1, 2014	Aug 1, 2015	Kidney Failure, Chronic
NCT01789086	Phase 1	Completed	Feb 1, 2013	May 1, 2014	Metabolism and Nutrition Disorder
NCT01755572	Approved	Completed	Jan 1, 2013	Mar 1, 2014	Type 2 Diabetes
NCT02113332	Phase 2	Completed	Jan 1, 2013	Aug 1, 2014	Type 2 Diabetes Mellitus

Competing Products

18 competing products in Gestational Diabetes Mellitus

See all competitors

Product	Company	Stage	Hype Score
somatropin	Eli Lilly	Phase 3	40
Insulin LISPRO + Insulin, Long-Acting and Insulin	Eli Lilly	Approved	43
Camrelizumab plus apatinib CohortA + Camrelizumab plus apatinib Cohort B	Jiangsu Hengrui Medicine	Phase 2	42
Pembrolizumab Injection [Keytruda]	Merck	Phase 2	31
recombinant somatropin	Merck	Pre-clinical	26
Recombinant human growth hormone (r-hGH)	Merck	Phase 3	32
Avelumab Injection + Methotrexate 1 GM Injection	Merck	Phase 1/2	39
Saizen® + Saizen®	Merck	Phase 3	40
Metformin + placebo	Novo Nordisk	Approved	39
Metformin XR plus placebo + Metformin XR plus liraglutide	Novo Nordisk	Phase 3	40
Somapacitan + Norditropin®	Novo Nordisk	Phase 2	39
Genotropin (PN-180,307) Somatropin + Control-no treatment	Pfizer	Phase 3	40
growth hormone	Pfizer	Pre-clinical	26
Somatropin	Pfizer	Pre-clinical	26
Somatropin	Pfizer	Pre-clinical	26
Genotropin (somatropin)	Pfizer	Approved	43
Omnitrope	Sandoz Group	Approved	40
Inhaled Technosphere Insulin	MannKind Corp	Phase 2/3	39